SHAREing & CAREing

NYC Cancer Support Services

Intermittent Fasting and Cancer: What Human Studies Reveal

Intermittent fasting and cancer—especially in the context of treatment or prevention—has become a growing interest in cancer research and patient care. Some claim fasting may reduce chemotherapy side effects. Others study its impact on cellular health to see if it can help prevent cancer or improve treatment outcomes—an area of research that could directly affect how future patients experience and recover from cancer therapy. 

But how much of the hype is supported by clinical evidence? Can intermittent fasting kill cancer cells? Is there a connection between breast cancer and intermittent fasting? This article breaks down what human studies say about the potential of intermittent fasting for cancer outcomes.

What Is Intermittent Fasting?

Intermittent fasting (IF) is a dietary pattern that cycles between periods of eating and voluntary fasting. It differs from continuous calorie restriction and may be easier to maintain for some individuals. Common IF methods studied in cancer research include:

  • Time-Restricted Eating (TRE): Eating within a set window each day (e.g., 10–12 hours) and fasting overnight
  • Prolonged Fasting or Fasting-Mimicking Diets (FMD): 2–5 day regimens around chemotherapy cycles
  • 5:2 or Alternate-Day Fasting: Fasting on two nonconsecutive days per week, often limited to 500–600 calories

These methods aim to lower insulin and IGF-1 (a growth-promoting hormone linked to cancer risk), reduce inflammation, support a healthy body weight, enhance cellular repair, and improve metabolic health—all factors that may affect cancer development and progression.

13 Ways Diet Can Fight Cancer

Intermittent Fasting and Chemotherapy: Is It Helpful?

Initial small studies and patient reports suggested fasting before chemotherapy might reduce side effects like nausea, fatigue, and bone marrow suppression (a drop in blood cell production that weakens the immune system). The theory is that normal cells enter a protective mode during fasting, while cancer cells remain vulnerable.

However, recent reviews and randomized trials have found no consistent benefit. A 2025 meta-analysis in BMC Cancer found that while fasting improved weight and metabolic markers, it did not significantly reduce chemotherapy toxicity. Similarly, the DIRECT trial, a study in breast cancer patients testing whether a fasting-mimicking diet could improve chemotherapy outcomes, found no meaningful differences in side effects or tumor response compared with a regular diet.

For now, leading organizations like the American Cancer Society and MD Anderson advise against using intermittent fasting during cancer treatment outside clinical trials.

Breast Cancer and Intermittent Fasting: What We Know

One of the most cited studies on intermittent fasting and cancer recurrence looked at women with early-stage breast cancer. Researchers found that those who fasted 13 or more hours overnight had a 36% lower risk of cancer recurrence compared to those who fasted less.

This was an observational study (which can show associations but not prove cause and effect), not a randomized trial, but it suggests that extending nightly fasting may support better glucose control and reduce inflammation, potentially lowering recurrence risk. This aligns with other findings that show IF can enhance metabolic health.

Can Intermittent Fasting Kill Cancer Cells?

In early lab studies in cells and animals, fasting appears to make cancer cells more susceptible to stress by depriving them of glucose and growth signals. It can also activate cellular self-cleaning processes like autophagy.

But no human studies have proven that intermittent fasting directly kills cancer cells or can replace treatment. For now, fasting is being explored as a complementary approach, particularly during survivorship or in supervised clinical settings.

Is Intermittent Fasting Safe for Everyone?

For healthy individuals, IF is generally safe. But for cancer patients, risks include unintended weight loss and malnutrition, which can weaken the body’s ability to recover.

Some emerging data also raise concerns. A recent animal study found that the refeeding phase after fasting increased tumor formation in genetically predisposed mice. This hasn’t been seen in humans but underscores the need for caution and further research.

Final Thoughts: A Tool, Not a Cure

Intermittent fasting shows promise in improving metabolic health, which is linked to lower cancer risk. For cancer survivors—especially those at risk of recurrence—moderate IF (such as 13-hour nightly fasts) may offer benefits. But for those in active treatment, IF should only be attempted with medical supervision.

For New York City residents and Queens communities navigating cancer, understanding tools like intermittent fasting within evidence-based care is essential. As a trusted cancer non-profit, SHAREing & CAREing is committed to providing clear, up-to-date health education for patients, survivors, and caregivers.

If you are considering fasting as part of your health strategy, talk to your doctor, contact us or reach out to our SHAREing & CAREing cancer patient survivorship program. We are survivors, too, and can help support you in your health journey.

Sources

Explore more

Please help us continue providing our vital cancer support services…

Donate Today